These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 33618740

  • 1. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2021 Feb 23; 14(1):32. PubMed ID: 33618740
    [No Abstract] [Full Text] [Related]

  • 2. m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2019 Dec 09; 12(1):135. PubMed ID: 31818312
    [Abstract] [Full Text] [Related]

  • 3. Retraction Note: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2023 Feb 22; 16(1):14. PubMed ID: 36814345
    [No Abstract] [Full Text] [Related]

  • 4. Correction to: m6A mRNA methylation initiated by METTL3 directly promotes YAP translation and increases YAP activity by regulating the MALAT1-miR-1914-3p-YAP axis to induce NSCLC drug resistance and metastasis.
    Jin D, Guo J, Wu Y, Du J, Yang L, Wang X, Di W, Hu B, An J, Kong L, Pan L, Su G.
    J Hematol Oncol; 2020 Aug 03; 13(1):106. PubMed ID: 32746876
    [Abstract] [Full Text] [Related]

  • 5. m6A demethylase ALKBH5 inhibits tumor growth and metastasis by reducing YTHDFs-mediated YAP expression and inhibiting miR-107/LATS2-mediated YAP activity in NSCLC.
    Jin D, Guo J, Wu Y, Yang L, Wang X, Du J, Dai J, Chen W, Gong K, Miao S, Li X, Sun H.
    Mol Cancer; 2020 Feb 27; 19(1):40. PubMed ID: 32106857
    [Abstract] [Full Text] [Related]

  • 6. Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis.
    Jin D, Guo J, Wu Y, Chen W, Du J, Yang L, Wang X, Gong K, Dai J, Miao S, Li X, Su G.
    J Exp Clin Cancer Res; 2020 Jan 06; 39(1):6. PubMed ID: 31906986
    [Abstract] [Full Text] [Related]

  • 7. MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.
    Du M, Zhang Y, Mao Y, Mou J, Zhao J, Xue Q, Wang D, Huang J, Gao S, Gao Y.
    Biochem Biophys Res Commun; 2017 Jan 22; 482(4):582-589. PubMed ID: 27856248
    [Abstract] [Full Text] [Related]

  • 8. CircPUM1 promotes cell growth and glycolysis in NSCLC via up-regulating METTL3 expression through miR-590-5p.
    Li M, Wang Q, Zhang X, Yan N, Li X.
    Cell Cycle; 2021 Jul 22; 20(13):1279-1294. PubMed ID: 34097560
    [Abstract] [Full Text] [Related]

  • 9. RBM10 recruits METTL3 to induce N6-methyladenosine-MALAT1-dependent modification, inhibiting the invasion and migration of NSCLC.
    Cao Y, Di X, Cong S, Tian C, Wang Y, Jin X, Zhao M, Zhou X, Li R, Wang K.
    Life Sci; 2023 Feb 15; 315():121359. PubMed ID: 36608868
    [Abstract] [Full Text] [Related]

  • 10. LncRNA MALAT1 contributes to non-small cell lung cancer progression via modulating miR-200a-3p/programmed death-ligand 1 axis.
    Wei S, Wang K, Huang X, Zhao Z, Zhao Z.
    Int J Immunopathol Pharmacol; 2019 Feb 15; 33():2058738419859699. PubMed ID: 31240979
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The m6A methyltransferase METTL3 affects cell proliferation and migration by regulating YAP expression in Hirschsprung disease.
    Huang Z, Luo C, Hou X, Yu D, Su Y, Li X, Luo Y, Liao G, Mu J, Wu K.
    Pediatr Surg Int; 2023 Feb 15; 39(1):126. PubMed ID: 36790471
    [Abstract] [Full Text] [Related]

  • 13. LncRNA MALAT1 promotes breast cancer progression and doxorubicin resistance via regulating miR-570-3p.
    Yue X, Wu WY, Dong M, Guo M.
    Biomed J; 2021 Dec 15; 44(6 Suppl 2):S296-S304. PubMed ID: 35410813
    [Abstract] [Full Text] [Related]

  • 14. METTL3 promotes adriamycin resistance in MCF-7 breast cancer cells by accelerating pri-microRNA-221-3p maturation in a m6A-dependent manner.
    Pan X, Hong X, Li S, Meng P, Xiao F.
    Exp Mol Med; 2021 Jan 15; 53(1):91-102. PubMed ID: 33420414
    [Abstract] [Full Text] [Related]

  • 15. METTL3 Promotes Tumorigenesis and Metastasis through BMI1 m6A Methylation in Oral Squamous Cell Carcinoma.
    Liu L, Wu Y, Li Q, Liang J, He Q, Zhao L, Chen J, Cheng M, Huang Z, Ren H, Chen J, Peng L, Gao F, Chen D, Wang A.
    Mol Ther; 2020 Oct 07; 28(10):2177-2190. PubMed ID: 32621798
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. MicroRNA-142-3p/MALAT1 inhibits lung cancer progression through repressing β-catenin expression.
    Liu J, Tian W, Zhang W, Jia Y, Yang X, Wang Y, Zhang J.
    Biomed Pharmacother; 2019 Jun 07; 114():108847. PubMed ID: 30970294
    [Abstract] [Full Text] [Related]

  • 18. N6-Methyladenosine-induced miR-143-3p promotes intervertebral disc degeneration by regulating SOX5.
    Gao D, Hu B, Ding B, Zhao Q, Zhang Y, Xiao L.
    Bone; 2022 Oct 07; 163():116503. PubMed ID: 35878746
    [Abstract] [Full Text] [Related]

  • 19. METTL3-Induced miR-222-3p Upregulation Inhibits STK4 and Promotes the Malignant Behaviors of Thyroid Carcinoma Cells.
    Lin S, Zhu Y, Ji C, Yu W, Zhang C, Tan L, Long M, Luo D, Peng X.
    J Clin Endocrinol Metab; 2022 Jan 18; 107(2):474-490. PubMed ID: 34562008
    [Abstract] [Full Text] [Related]

  • 20. miR-302a-3p suppresses melanoma cell progression via targeting METTL3.
    Chang X, Lin YY, Bai LN, Zhu W.
    J Chemother; 2022 Feb 18; 34(1):55-66. PubMed ID: 34286671
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.